Novartis: Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval. read more
Read full article »
Novartis is a Switzerland-based multinational medicines company that researches and develops generic and pharmaceutical products for the healthcare industry.
Read more